| 摘要 |
<p>HIV-1 peptides having at least one point mutation between position 593 and 611 of the HIV-1 gp 160 amino acid sequence. The point mutation either is at position 604 or 610, or both positions. Immunoassays which utilize these peptides are provided, as well as, diagnostic test kits which contain these peptides.</p> |
